Skip to main content
Independent federal grant matching. Not affiliated with any government agency. Get free access and see which open grants fit your organization.
Closed on Oct 14, 2026

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

National Institutes of Health · Opportunity number PAR-25-074

Details summarized from the official notice as of Oct 15, 2026. Always confirm eligibility, deadlines and requirements in the official notice before applying.

Independent platform. Not affiliated with or endorsed by any government agency. Data from public federal sources.

This opportunity is closed as of Oct 14, 2026. It is kept here for reference. See the related open opportunities below, or check the official listing in case the agency posts a new cycle.

Key facts

Opportunity numberPAR-25-074
AgencyNational Institutes of Health
Department of Health and Human Services
Assistance listing (ALN, formerly CFDA)93.394
PostedOct 15, 2024
DeadlineOct 14, 2026
Cost sharing or matching requiredNo
Funding typeCooperative agreement
CategoryEducation
Last updated hereOct 15, 2026

Summary from the notice

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this NOFO supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this NOFO supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientist.

Who can apply

The official notice lists these applicant types as eligible:

  • For-profit organizations other than small businesses
  • Small businesses
  • Nonprofits with 501(c)(3) status (other than colleges)
  • Private colleges and universities
  • County governments
  • State governments
  • Nonprofits without 501(c)(3) status (other than colleges)
  • Independent school districts
  • Federally recognized tribal governments
  • Other Native American tribal organizations
  • Others named in the notice (see the eligibility text)
  • City or township governments
  • Public and Indian housing authorities
  • Public and state colleges and universities
  • Special district governments

Who should take a closer look

  • Small businesses
  • Nonprofits
  • Colleges and universities
  • State governments
  • Local governments
  • Tribal governments and organizations
  • Larger for-profit companies

Not listed as eligible

  • Individuals

Unless the eligibility text in the notice names you, this opportunity is probably not for you.

Eligibility details from the notice

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Registrations you will likely need

Most applications submitted through Grants.gov need the following. Registration can take several weeks, so start early. The notice lists the exact requirements.

Related open opportunities

Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)

National Institutes of Health · PAR-25-155

Deadline: Oct 19, 2026 (3 days left) Up to: $50,000 Health

Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

National Institutes of Health · RFA-CA-27-021

Deadline: Oct 19, 2026 (3 days left) Up to: $600,000 Health

Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

National Institutes of Health · RFA-CA-27-020

Deadline: Oct 19, 2026 (3 days left) Up to: $600,000 Health